Bad Miss For Biocon’s Bevacizumab In US But Firm In 'Good Place'

Bicara To Raise Funds In The Coming Fiscal Year

 
• By Anju Ghangurde
Pandemic induced misses dull momentum for Biocon • Source: Alamy

More from Business

More from Scrip